Document is current
Any future updates will be listed below
-
Authors
Palevičiūtė, Eglė https://orcid.org/0000-0003-4758-7833
Šimbelytė, Toma https://orcid.org/0000-0002-7571-6383
Eichstaedt, Christina A. https://orcid.org/0000-0001-7288-8297
Benjamin, Nicola https://orcid.org/0000-0003-4730-969X
Egenlauf, Benjamin https://orcid.org/0000-0003-2466-1420
Grünig, Ekkehard https://orcid.org/0000-0001-7318-3918
Čelutkienė, Jelena https://orcid.org/0000-0003-3562-9274
- License Information
-
More Information
Article History
Accepted: 23 June 2022
First Online: 13 July 2022
Declarations
:
: Due to the design of the trial (literature review), the study was exempted from requiring ethics approval.
: The author E.P. reports speaker honoraria fees from Johnson and Johnson and Medis Pharma outside this work. The authors T.Š., C.A.E, N.B., and B.E. have no competing interests to declare. The author E.G. reports research grants and speaker honoraria/consultancy fees from Actelion, Janssen, Bayer, MSD, Merck, and Ferrer and research grants to the institution from Acceleron, Actelion, Bayer, MSD, Janssen, Liquidia, United Therapeutics, and OMT outside the submitted work. The author J.Č. reports personal fees from AstraZeneca, Boehringer Ingelheim, Pfizer, Bayer, and Novartis outside this work.
